# Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

> **NCT01696045** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 14 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01696045
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11-12
- **Primary completion:** 2016-07-31
- **Final completion:** 2016-07-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2017-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696045, "Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01696045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*